The receptor activator of nuclear factor-κB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism

Calcified Tissue International

Volumn 78, Issue 1, 2006, Pages 35-44

  Padagas, J ^a   Colloton, M ^a   Shalhoub, V ^a   Kostenuik, P ^a   Morony, S ^a   Munyakazi, L ^a   Guo, M ^a   Gianneschi, D ^a   Shatzen, E ^a   Geng, Z ^a   Tan, H L ^a   Dunstan, C ^b   Lacey, D ^a   Martin, D ^a  

^a AMGEN INC   (United States)

^b Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

5 6 nephrectomy; Chronic kidney disease; Fibrous osteodystrophy; Osteitis fibrosa; Secondary hyperparathyroidism

Indexed keywords

AMG 0007; CALCIUM; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PROTECTIVE AGENT; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CALCIUM INTAKE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG TARGETING; DUAL ENERGY X RAY ABSORPTIOMETRY; EXAMINATION; HUMAN; HUMAN CELL; HYPERPARATHYROIDISM; LEG; LUMBAR SPINE; MALE; METAPHYSIS; NEPHRECTOMY; NONHUMAN; OSTEITIS FIBROSA; OSTEOLYSIS; OSTEOPENIA; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN TARGETING; RAT; THICKNESS; TIBIA; TRABECULAR BONE;

ANIMALS; CARRIER PROTEINS; DENSITOMETRY, X-RAY; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; HUMANS; HYPERPARATHYROIDISM; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANE GLYCOPROTEINS; OSTEOPROTEGERIN; PARATHYROID HORMONE; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 30844439149     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-005-0161-1     Document Type: Article

References (37)

1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
2. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ (2000) Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157:435-448
3. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342
4. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348-360
5. Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR (2001) OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142:4295-4304
6. Capparelli C, Kostenuik PJ, Morony S, Starnes C, Weimann B, G Van , Scully S, Qi M, Lacey DL, Dunstan CR (2000) Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 60:783-787
7. Akatsu T, Murakami T, Ono K, Nishikawa M, Tsuda E, Mochizuki SI, Fujise N, Higashio K, Motoyoshi K, Yamamoto M, Nagata N (1998) Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 23:495-498
8. Doran PM, Turner RT, Chen D, Facteau SM, Ludvigson JM, Khosla S, Riggs BL, Russell SJ (2004) Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts. Exp Hematol 32:351-359
9. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527-3533
10. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97(suppl 3):887-892
11. Cheng X, Kinosaki M, Murali R, Greene MI (2003) The TNF receptor superfamily: role in immune inflammation and bone formation. Immunol Res 27:287-294
12. Vanderkerken K, Asosingh K, Croucher P, Van Camp B (2003) Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev 194:196-206
13. Wittrant Y, Theoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, Redini F (2004) RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 1704:49-57
14. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61:4432-4436
15. Bolon B, Shalhoub V, Kostenuik PJ, Campagnuolo G, Morony S, Boyle WJ, Zack D, Feige U (2002) Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. Arthritis Rheum 46:3121-3135
16. Goodman WG, Coburn JW, Slatopolsky E, Salusky IB, Quarles LD (2003) Renal osteodystrophy in adults and children In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. American Society for Bone and Mineral Research, Washington DC, pp 430-447
17. Parfitt AM (1998) A structural approach to renal bone disease. J Bone Miner Res 13:1213-1220
18. Jablonski G, Klem KH, Attramadal A, Dahl E, Ronningen H, Gautvik KM, Haug E, Gordeladze JO (1993) Surgically induced uremia in rats. I: Effect on bone strength and metabolism. Biosci Rep 13:275-287
19. Jablonski G, Danielsen CC, Mosekilde L, Gordeladze JO (1994) Surgically induced uremia in rats. II: Osseous PTH-susceptible signaling systems as predictors of bone resorption. Calcif Tissue Int 55:281-287
20. Miller MA, Chin J, Miller SC, Fox J (1998) Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Bone 23:257-266
21. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N (1998) NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53:448-453
22. 3 analogs and salmon calcitonin partially reverse the development of renal osteodystrophy in rats. Calcif Tissue Int 57:385-391
23. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42:1228-1236
24. Avbersek-Luznik I, Balon BP, Rus I, Marc J (2005) Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrol Dial Transplant 20:566-570
25. Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA (2004) PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 19:235-244
26. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602
27. Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349:1676-1678
28. Ammann P, Rizzoli R, Slosman D, Bonjour J-P (1992) Sequential and precise in vivo measurement of bone mineral density in rats using dual-energy X-ray absorptiometry. J Bone Miner Res 7:311-316
29. Makan S, Bayley HS, Webber CE (1997) Precision and accuracy of total body bone mass and body composition measurements in the rat using X-ray-based dual photon absorptiometry. Can J Physiol Pharmacol 75:1257-1261
30. Colloton M, Shatzen E, Miller G, Stehman-Ereen C, Wada M, Lacey DL, Martin D (2005) Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67:467-476
31. Lee SK, Lorenzo JA (2002) Regulation of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase A pathway in murine bone marrow cultures. Bone 31:252-259
32. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE (2001) Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinol 142:4047-4054
33. Geng Z, Monier-Faugere MC, Bauss F, Malluche HH (2000) Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure. Clin Nephrol 54:45-53
34. Moscovici A, Bernheim J, Popovtzer MM, Rubinger D (1996) Renal osteodystrophy in rats with reduced renal mass. Nephrol Dial Transplant 11(suppl 3):146-152
35. Kazama JJ, Iwasaki Y, Yamato H, Murayama H, Sato M, Gejyo F, Kurokawa M, Fukagawa K (2003) Microfocus computed tomography analysis of early changes in bone microstructure in rats with chronic renal failure. Nephron Exp Nephrol 95:e152-e157
36. Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S, Kostenuik PJ (2003) Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 18:852-858
37. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D'Agati VD (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281-289